{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-21-000039","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2021-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.561693+00:00","generated_at":"2026-06-30T02:15:14.805233+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"10x Genomics settles all patent litigation with Bio-Rad, enters global cross-license for single cell analysis","bullets":["Cross license covers single cell analysis; excludes spatial, in situ, and digital PCR (for 10x).","10x to pay Bio-Rad $29.4M in royalties/interest for past GEM sales; $15.4M reversal in Q2 2021.","Future royalty payments expected to impact gross margins by less than 1% through 2030.","All outstanding litigation dismissed with prejudice.","Agreement term is life of licensed patents."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-21-000039","json":"https://secwatch.observer/filing/0001770787-21-000039.json","markdown":"https://secwatch.observer/filing/0001770787-21-000039.md","text":"https://secwatch.observer/filing/0001770787-21-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078721000039/0001770787-21-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078721000039/txg-20210726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:15:14.805233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}